Literature DB >> 21430223

Tumors suppress in situ proliferation of cytotoxic T cells by promoting differentiation of Gr-1(+) conventional dendritic cells through IL-6.

Jun Diao1, Jun Zhao, Erin Winter, Mark S Cattral.   

Abstract

Cancers are often accompanied by inflammation, which can promote tumor growth, invasion, and metastases. We show that the tumor microenvironment induces the development of a Gr-1(+) conventional dendritic cell (cDC) subpopulation that is functionally defective. Gr-1(+)cDCs differentiated from recruited immediate precursors of cDCs, a process supported by the inflammatory cytokine milieu in tumors. Inhibition of Gr-1(+)cDC differentiation enhanced intratumor expansion of cytotoxic CD8(+) T cells (CTLs), resulting in suppression of tumor growth. Diphtheria toxin treatment of CD11c-diphtheria toxin receptor chimeras revealed the importance of intratumor cDCs in stimulating CTL proliferation in situ. Our study demonstrates a key role of intratumor cDCs in determining antitumor CTL responses and suggests that they may be an appropriate target for tumor immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21430223     DOI: 10.4049/jimmunol.1004125

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  Molecular mechanisms involved in dendritic cell dysfunction in cancer.

Authors:  Michael Tang; Jun Diao; Mark S Cattral
Journal:  Cell Mol Life Sci       Date:  2016-08-05       Impact factor: 9.261

2.  Tumor Dendritic Cells (DCs) Derived from Precursors of Conventional DCs Are Dispensable for Intratumor CTL Responses.

Authors:  Jun Diao; Hongtao Gu; Michael Tang; Jun Zhao; Mark S Cattral
Journal:  J Immunol       Date:  2018-07-11       Impact factor: 5.422

Review 3.  Pathological mobilization and activities of dendritic cells in tumor-bearing hosts: challenges and opportunities for immunotherapy of cancer.

Authors:  Amelia J Tesone; Nikolaos Svoronos; Michael J Allegrezza; Jose R Conejo-Garcia
Journal:  Front Immunol       Date:  2013-12-10       Impact factor: 7.561

4.  Mesothelioma tumor cells modulate dendritic cell lipid content, phenotype and function.

Authors:  Joanne K Gardner; Cyril D S Mamotte; Priya Patel; Teong Ling Yeoh; Connie Jackaman; Delia J Nelson
Journal:  PLoS One       Date:  2015-04-17       Impact factor: 3.240

Review 5.  STING, DCs and the link between innate and adaptive tumor immunity.

Authors:  Ralph E Vatner; Edith M Janssen
Journal:  Mol Immunol       Date:  2017-12-20       Impact factor: 4.407

Review 6.  Myeloid Immune Cells CARrying a New Weapon Against Cancer.

Authors:  Rodrigo Nalio Ramos; Samuel Campanelli Freitas Couto; Theo Gremen M Oliveira; Paulo Klinger; Tarcio Teodoro Braga; Eduardo Magalhães Rego; José Alexandre M Barbuto; Vanderson Rocha
Journal:  Front Cell Dev Biol       Date:  2021-12-10

7.  Melanoma-infiltrating dendritic cells: Limitations and opportunities of mouse models.

Authors:  Jared S Klarquist; Edith M Janssen
Journal:  Oncoimmunology       Date:  2012-12-01       Impact factor: 8.110

Review 8.  Synergistic Effect and Molecular Mechanisms of Traditional Chinese Medicine on Regulating Tumor Microenvironment and Cancer Cells.

Authors:  Jingnan Xu; Zhuo Song; Qiujun Guo; Jie Li
Journal:  Biomed Res Int       Date:  2016-03-02       Impact factor: 3.411

Review 9.  DCision-making in tumors governs T cell anti-tumor immunity.

Authors:  Francesca Alfei; Ping-Chih Ho; Wan-Lin Lo
Journal:  Oncogene       Date:  2021-07-21       Impact factor: 9.867

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.